On August 16, 2024, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. officially launched its groundbreaking “oneClick+” Antibody Design Platform.
The oneClick+ Platform, developed by Sanyou Bio, integrates 90% of mainstream antibody structures from current market data and literature. The platform includes four primary systems: “IgG-like antibody,” “Nanobody (VHH),” “Single-chain Fragment Variable antibody (ScFv),” and “VHH+ScFv,” offering over 100 configurations for enhanced antibody design capabilities.
Users can design antibodies on the oneClick+ platform through two methods:
- Enter the complete antibody sequence, including both variable and constant regions, to allow the system to automatically align sequences and generate physicochemical properties and mutation reports.
- Input only the variable region sequence, with constant regions selected from the Sanyou Bio database. The platform will then generate an antibody report with basic physicochemical details, configuration diagrams, and complete sequences.
The oneClick+ platform simplifies antibody design, eliminating the need for complex patent searches and software integration. Users can quickly generate desired antibody sequences or structural diagrams with just a few clicks.
Dr. Guojun Lang, CEO of Sanyou Bio, emphasized, “As intelligent technology advances, the intelligent development of biologic drugs has become essential. The oneClick+ platform represents a major advancement for Sanyou Bio in intelligent antibody design, offering convenience that will transform how users approach the process. We anticipate that the platform will greatly enhance customer experience and contribute to the progress of the biopharmaceutical industry.”
